Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021

Xinren Che; Qinghua Chen; Yan Liu; Lintao Gu; Zhaojun Lu; Wenwen Gu; Jun Wang; Wei Jiang; Jian Du; Xiaoping Zhang; Yuyang Xu; Xuechao Zhang; Jing Wang; Qixin Xie; Yingying Yang

doi:10.3389/fpubh.2023.1184059

Analysis of 13-valent pneumococcal polysaccharide conjugate vaccine among children born in Hangzhou from 2017 to 2021

Front Public Health. 2023 May 30:11:1184059. doi: 10.3389/fpubh.2023.1184059. eCollection 2023.

Authors

Xinren Che¹, Qinghua Chen², Yan Liu¹, Lintao Gu¹, Zhaojun Lu¹, Wenwen Gu¹, Jun Wang¹, Wei Jiang¹, Jian Du¹, Xiaoping Zhang¹, Yuyang Xu¹, Xuechao Zhang¹, Jing Wang¹, Qixin Xie¹, Yingying Yang¹

Affiliations

¹ Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
² Department of Expanded Program on Immunization, Linping Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.

Abstract

Background: 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) has been introduced in Hangzhou since 2017, whereas its current immunization state in children is not clear. Therefore, this study aims to describe the PCV13 vaccination distribution among children born in Hangzhou from 2017 to 2021 to provide data for reducing vaccination differences among different populations.

Methods: Descriptive epidemiology was used for data analysis and PCV13 vaccination related information of children was collected from children vaccination management system of Zhejiang Province (ZJCVMS).

Results: Among the 649,949 children born in Hangzhou from 2017 to 2021, 169,230 were vaccinated with an average full course vaccination rate of 26.0%. The full course vaccination rates in 5 years were different (P = 0.000) with an increasing trend (P _fortrend < 0.01). The first dose vaccination rates were different in 5 years (P = 0.000) with an increasing trend (P _fortrend < 0.01). The distribution of age when first dose PCV13 was administered varied, most people at 2 months and least people at 5 months. The full course vaccination rate varied by areas, highest in central urban areas and lowest in remote areas respectively (all P-value < 0.05). Overall, the full course vaccination rate of PCV13 was higher in the registered residence population than the non-registered residence population, which was 136,693 (31.4%) and 32,537 (15.1%) respectively (P = 0.000). The full course vaccination rates were the same between men and women (P = 0.502), which was 87,844 for men (26.0%) and 81,386 for women (26.1%).

Conclusion: Although the number of people who received PCV13 full course vaccination and received the first dose vaccination showed yearly increasing trends in Hangzhou, the full course vaccination rate for the whole population was relatively low. In addition, the PCV13 vaccination rates also differed by geography and household registration status. Measures such as expanding vaccination publicity or including national immunization should be taken to increase vaccination rates and reduce the differences in vaccination among groups with different characteristics.

Keywords: 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13); Hangzhou; all-course vaccination rate; children; first vaccination rate.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Bacterial*
Child
Female
Humans
Infant
Male
Pneumococcal Vaccines
Polysaccharides
Streptococcus pneumoniae*
Vaccination
Vaccines, Conjugate

Substances

Vaccines, Conjugate
Antibodies, Bacterial
Pneumococcal Vaccines
Polysaccharides

Grants and funding

This research was funded by Basic Public Welfare Research Program of Zhejiang Province (LGF22H260012) and Hangzhou Health Science and Technology Plan project (A20230277).